Cullinan Oncology, Inc. NASDAQ:CGEM

Founder-led company

Cullinan Oncology stock price today

$7.51
-4.51
-37.52%
Financial Health
0
1
2
3
4
5
6
7
8
9

Cullinan Oncology stock price monthly change

-26.93%
month

Cullinan Oncology stock price quarterly change

-26.93%
quarter

Cullinan Oncology stock price yearly change

+19.25%
year

Cullinan Oncology key metrics

Market Cap
676.89M
Enterprise value
N/A
P/E
4.46
EV/Sales
N/A
EV/EBITDA
-44.29
Price/Sales
N/A
Price/Book
N/A
PEG ratio
0.01
EPS
-3.15
Revenue
N/A
EBITDA
-170.20M
Income
-132.34M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Cullinan Oncology stock price history

Cullinan Oncology stock forecast

Cullinan Oncology financial statements

Average Price Target
Last Year

$34

Potential upside: 352.72%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Cullinan Oncology, Inc. (NASDAQ:CGEM): Profit margin
Jun 2023 0 -32.21M
Sep 2023 0 -39.18M
Dec 2023 0 -23.80M
Mar 2024 0 -37.14M
Cullinan Oncology, Inc. (NASDAQ:CGEM): Earnings per share (EPS)
2024-03-14 -0.96 -0.54
Cullinan Oncology, Inc. (NASDAQ:CGEM): Debt to assets
Jun 2023 521984000 22.41M 4.29%
Sep 2023 494707000 25.89M 5.23%
Dec 2023 485096000 31.20M 6.43%
Mar 2024 449430000 23.76M 5.29%
Cullinan Oncology, Inc. (NASDAQ:CGEM): Cash Flow
Jun 2023 -31.00M 12.11M 38.60M
Sep 2023 -34.14M -42.95M 112K
Dec 2023 -18.13M 51.47M 248K
Mar 2024 -38.24M 12.95M 1.08M

Cullinan Oncology alternative data

Cullinan Oncology, Inc. (NASDAQ:CGEM): Employee count
Aug 2023 62
Sep 2023 62
Oct 2023 62
Nov 2023 62
Dec 2023 62
Jan 2024 62
Feb 2024 62
Mar 2024 85
Apr 2024 85
May 2024 85
Jun 2024 85
Jul 2024 85

Cullinan Oncology other data

82.54% +3.03%
of CGEM is owned by hedge funds
37.64M +769.35K
shares is hold by hedge funds

Cullinan Oncology, Inc. (NASDAQ:CGEM): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 80000
Feb 2024 0 40000
May 2024 0 63606
Jul 2024 0 8000
Sep 2024 0 8000
Nov 2024 0 8000
Dec 2024 0 3489
Transaction Date Insider Security Shares Price per share Total value Source
Sale
MICHAELSON JENNIFER officer: Chief Scientific Officer
Common Stock 3,489 $12.52 $43,682
Sale
MICHAELSON JENNIFER officer: Chief Scientific Officer
Common Stock 8,000 $15.64 $125,120
Sale
MICHAELSON JENNIFER officer: Chief Scientific Officer
Common Stock 8,000 $18.09 $144,720
Sale
MICHAELSON JENNIFER officer: Chief Scientific Officer
Common Stock 8,000 $16.33 $130,640
Option
EBELING THOMAS director
Common Stock 18,450 $13 $239,850
Option
EBELING THOMAS director
Stock Option (Right to Buy) 18,450 $13 $239,850
Option
EBELING THOMAS director
Stock Option (Right to Buy) 100,699 $8.52 $857,452
Option
MICHAELSON JENNIFER officer: Chief Scientific Officer
Common Stock 5,606 $4.3 $24,106
Option
MICHAELSON JENNIFER officer: Chief Scientific Officer
Stock Option (Right to Buy) 5,606 $4.3 $24,106
Sale
MICHAELSON JENNIFER officer: Chief Scientific Officer
Common Stock 5,606 $30.06 $168,516
Thursday, 14 November 2024
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
Monday, 4 November 2024
globenewswire.com
Wednesday, 16 October 2024
globenewswire.com
Tuesday, 17 September 2024
globenewswire.com
Saturday, 14 September 2024
globenewswire.com
Wednesday, 28 August 2024
globenewswire.com
Saturday, 1 June 2024
globenewswire.com
Friday, 24 May 2024
globenewswire.com
Thursday, 23 May 2024
globenewswire.com
Wednesday, 15 May 2024
globenewswire.com
Monday, 29 April 2024
globenewswire.com
Wednesday, 24 April 2024
GlobeNewsWire
Monday, 18 December 2023
GlobeNewsWire
Monday, 30 October 2023
GlobeNewsWire
Monday, 31 July 2023
GlobeNewsWire
Friday, 9 June 2023
The Motley Fool
Thursday, 25 May 2023
GlobeNewsWire
Wednesday, 26 April 2023
GlobeNewsWire
Tuesday, 14 March 2023
GlobeNewsWire
Tuesday, 1 November 2022
GlobeNewsWire
Thursday, 22 September 2022
Seeking Alpha
Wednesday, 14 September 2022
Seeking Alpha
Wednesday, 7 September 2022
GlobeNewsWire
Thursday, 19 May 2022
GlobeNewsWire
Thursday, 12 May 2022
Benzinga
Wednesday, 9 March 2022
GlobeNewsWire
Tuesday, 8 March 2022
GlobeNewsWire
Monday, 7 February 2022
GlobeNewsWire
Wednesday, 5 January 2022
Pulse2
  • What's the price of Cullinan Oncology stock today?

    One share of Cullinan Oncology stock can currently be purchased for approximately $7.51.

  • When is Cullinan Oncology's next earnings date?

    Unfortunately, Cullinan Oncology's (CGEM) next earnings date is currently unknown.

  • Does Cullinan Oncology pay dividends?

    No, Cullinan Oncology does not pay dividends.

  • How much money does Cullinan Oncology make?

    Cullinan Oncology has a market capitalization of 676.89M. Cullinan Oncology made a loss 153.16M US dollars in net income (profit) last year or -$0.54 on an earnings per share basis.

  • What is Cullinan Oncology's stock symbol?

    Cullinan Oncology, Inc. is traded on the NASDAQ under the ticker symbol "CGEM".

  • What is Cullinan Oncology's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Cullinan Oncology?

    Shares of Cullinan Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Cullinan Oncology's key executives?

    Cullinan Oncology's management team includes the following people:

    • Dr. Patrick A. Baeuerle Ph.D. Co-Founder & Acting Chief Scientific Officer of Biologics(age: 67, pay: $737,930)
    • Mr. Owen P. Hughes Jr. Strategic Advisor(age: 50, pay: $720,560)
  • Is Cullinan Oncology founder-led company?

    Yes, Cullinan Oncology is a company led by its founder Dr. Patrick A. Baeuerle Ph.D..

  • How many employees does Cullinan Oncology have?

    As Jul 2024, Cullinan Oncology employs 85 workers.

  • When Cullinan Oncology went public?

    Cullinan Oncology, Inc. is publicly traded company for more then 4 years since IPO on 8 Jan 2021.

  • What is Cullinan Oncology's official website?

    The official website for Cullinan Oncology is cullinanoncology.com.

  • Where are Cullinan Oncology's headquarters?

    Cullinan Oncology is headquartered at One Main Street, Cambridge, MA.

  • How can i contact Cullinan Oncology?

    Cullinan Oncology's mailing address is One Main Street, Cambridge, MA and company can be reached via phone at +61 74104650.

  • What is Cullinan Oncology stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Cullinan Oncology in the last 12 months, the avarage price target is $34. The average price target represents a 352.72% change from the last price of $7.51.

Cullinan Oncology company profile:

Cullinan Oncology, Inc.

cullinanoncology.com
Exchange:

NASDAQ

Full time employees:

85

Industry:

Biotechnology

Sector:

Healthcare

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

One Main Street
Cambridge, MA 02142

CIK: 0001789972
ISIN: US2300311063
CUSIP: 230031106